ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.
A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...
An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback